HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nonprofit Pharmaceutical Companies

465.963

-0.190-0.04%

Number of Gainers:10

Number of Losers:17

Number of Flat:7

PE:- -

High:470.854

Open:466.355

Low:458.442

Close:466.153

Loading ...

CanSino Biologics Narrows Loss in Q1

MT Newswires Live

Alphamab Oncology - Interim Analysis of Phase Ii/Iii Clinical Trial of Kn026 Met Primary Endpoint of Pfs

THOMSON REUTERS

Ascentage Pharma Presents Results of Five Preclinical Studies for Anti-Cancer Drugs

MT Newswires Live

Akeso Gets China Nod for Lung Cancer Drug Indication

MT Newswires Live

Ivonescimab Receives Nmpa Approval for First-Line Treatment of Pd-L1-Positive Nsclc, Based on Breakthrough Head to Head Phase Iii Trial Demonstrating Superior Efficacy Over Pembrolizumab

THOMSON REUTERS

BRIEF-Zylox-Tonbridge Medical Technology Recommends Distribution Of Final Dividend Of RMB0.1 Per Share

BRIEF-Zylox-Tonbridge Medical Technology Says Intention To Conduct On-Market Share Repurchase

Zylox-Tonbridge Medical Technology - Recommends Distribution of Final Dividend of RMB0.1 per Share

THOMSON REUTERS

Zylox-Tonbridge Medical Technology - Intention to Conduct on-Market Share Repurchase to Amount Not Exceeding HKD650 Mln

THOMSON REUTERS

InnoCare Pharma Gets China Nod for Lymphoma Drug

MT Newswires Live

BRIEF-Keymed Biosciences Announces Approval Of IND For Cm518d1 By The National Medical Products Administration Of China

KeyMed Biosciences Announces Approval of Ind for Cm518d1 by the National Medical Products Administration of China for the Treatment of Solid Tumors

THOMSON REUTERS

KeyMed Biosciences Announces Approval of Ind for Cm518d1 by the National Medical Products Administration of China for the Treatment of Solid Tumors

THOMSON REUTERS

Everest Medicines to Drop B Marker from Stock Short Name

MT Newswires Live

US FDA Approves Nasopharyngeal Carcinoma Drug

MT Newswires Live

KeyMed Biosciences Announces Approval of Ind for Cm518d1 by the National Medical Products Administration of China for the Treatment of Gastrointestinal Cancers

THOMSON REUTERS

KeyMed Biosciences Announces Approval of Ind for Cm518d1 by the National Medical Products Administration of China for the Treatment of Gastrointestinal Cancers

THOMSON REUTERS

BRIEF-Akeso Says FDA Approved Anniko (Penpulimab-Kcqx, Pd-1) In Two Indications

Akeso Announces FDA Approval for Penpulimab-Kcqx in Two Bla Indications for Comprehensive Treatment of Advanced Nasopharyngeal Carcinoma

THOMSON REUTERS

Akeso - FDA Approved Anniko (Penpulimab-Kcqx, Pd-1) in Two Indications for Comprehensive Treatment of Advanced Nasopharyngeal Carcinoma

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK1574/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":465.96255,"timestamp":1746000495831,"preClose":466.15277,"halted":0,"volume":90926529,"delay":0,"changeRate":-0.000408,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed Labour Day","change":-0.190216,"latestTime":"04-30 16:00:00","open":466.35526,"high":470.85376,"low":458.44226,"amount":2573153749,"amplitude":0.026625,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1746149400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1745976600000,1745985600000],[1745989200000,1746000000000]],"pbRate":3.89505,"peRate":-23.354671,"turnoverRate":0.003412,"increases":10,"decrements":21,"flats":2,"marketCap":269853969728,"floatMarketCap":248722156224},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":470.85376,"amplitude":0.026625,"preClose":466.15277,"low":458.44226,"pbRate":"3.89505","latestPrice":465.96255,"volume":90926529,"delay":0,"open":466.35526,"prevYearClose":331.1933,"prevWeekClose":490.526,"prevMonthClose":465.963,"prevQuarterClose":455.082,"fiveDayClose":475.823,"twentyDayClose":459.856,"sixtyDayClose":321.772,"secType":"PLATE","market":"HK","turnoverRate":0.003412,"peRate":-23.354671,"marketCap":269853969728,"floatMarketCap":248722156224,"timestamp":1746000495831,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":10,"down":17,"flat":7},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531037204","title":"CanSino Biologics Narrows Loss in Q1","url":"https://stock-news.laohu8.com/highlight/detail?id=2531037204","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531037204?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:54","pubTimestamp":1746017675,"startTime":"0","endTime":"0","summary":"CanSino Biologics  narrowed its attributable loss in the first quarter to 11.5 million yuan from 170.1 million yuan in the year-ago period, a Tuesday Hong Kong bourse filing said.Loss per share stood at 0.05 yuan, down from 0.69 yuan in the same period of the last fiscal year.The vaccine manufacturer saw its operating revenue for the three months rise by 20% to 137.2 million yuan from 114.3 million yuan a year prior.The firm attributed the lower loss mainly to an increase in operating revenue amid a rising market share of its vaccine product Menhycia in China, a rise in other income due to government grants and international funding support, and reduced spillover costs.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1574","06185","BK1515","688185","BK0239","BK1161","BK1191"],"gpt_icon":0},{"id":"2531035634","title":"Alphamab Oncology - Interim Analysis of Phase Ii/Iii Clinical Trial of Kn026 Met Primary Endpoint of Pfs","url":"https://stock-news.laohu8.com/highlight/detail?id=2531035634","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531035634?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:29","pubTimestamp":1746012559,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nFWN3R81QD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["09966","BK1574","BK1161"],"gpt_icon":0},{"id":"2531274471","title":"Ascentage Pharma Presents Results of Five Preclinical Studies for Anti-Cancer Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2531274471","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531274471?lang=en_us&edition=fundamental","pubTime":"2025-04-29 16:46","pubTimestamp":1745916373,"startTime":"0","endTime":"0","summary":"Ascentage Pharma  presented the results of five preclinical studies at the meeting of the American Association for Cancer Research in Chicago, according to a Monday filing with the Hong Kong bourse.The presentations, in poster form, are for its olverembatinib and lisaftoclax drugs for acute myeloid leukemia, as well as APG-5918 for prostate cancer, APG-2449 for small-cell lung cancer, and AS03157 for apoptosis protein inhibition or cell death prevention, the filing said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","06855","BK1574"],"gpt_icon":0},{"id":"2530842448","title":"Akeso Gets China Nod for Lung Cancer Drug Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=2530842448","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530842448?lang=en_us&edition=fundamental","pubTime":"2025-04-28 14:13","pubTimestamp":1745820829,"startTime":"0","endTime":"0","summary":"Akeso  obtained approval for a supplementary new drug application for ivonescimab to treat non-small cell lung cancer from China's National Medical Products Administration, an April 25 Hong Kong bourse filing said.The approval is for the indication of use of the drug as a monotherapy for the first-line treatment of PD-L1-positive  non-small cell lung cancer patients.This indication marks the second major approval for ivonescimab, according to the drug company.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B543WZ88.USD","LU0348783233.USD","LU0348784397.USD","LU2488822045.USD","IE00B5MMRT66.SGD","09926","LU1720050803.USD","IE00BPRC5H50.USD","BK1161","LU1794554557.SGD","LU0417516571.SGD","BK1574"],"gpt_icon":1},{"id":"2530996168","title":"Ivonescimab Receives Nmpa Approval for First-Line Treatment of Pd-L1-Positive Nsclc, Based on Breakthrough Head to Head Phase Iii Trial Demonstrating Superior Efficacy Over Pembrolizumab","url":"https://stock-news.laohu8.com/highlight/detail?id=2530996168","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530996168?lang=en_us&edition=fundamental","pubTime":"2025-04-26 01:24","pubTimestamp":1745601857,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nTUAJZ8R1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["09926","IE00BPRC5H50.USD","IE00B543WZ88.USD","LU1794554557.SGD","BK1574","LU1720050803.USD","LU0348784397.USD","LU2488822045.USD","BK1161","LU0417516571.SGD","IE00B5MMRT66.SGD","LU0348783233.USD"],"gpt_icon":0},{"id":"2530315229","title":"BRIEF-Zylox-Tonbridge Medical Technology Recommends Distribution Of Final Dividend Of RMB0.1 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2530315229","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530315229?lang=en_us&edition=fundamental","pubTime":"2025-04-26 00:31","pubTimestamp":1745598679,"startTime":"0","endTime":"0","summary":"BRIEF-Zylox-Tonbridge Medical Technology Recommends Distribution Of Final Dividend Of RMB0.1 Per ShareApril 25  - Zylox-Tonbridge Medical Technology Co Ltd 2190.HK:RECOMMENDS DISTRIBUTION OF FINAL DIVIDEND OF RMB0.1 PER SHAREFurther company coverage: 2190.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nFWN3R30D7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02190","BK1587","BK1583","BK1100","BK1574"],"gpt_icon":0},{"id":"2530539391","title":"BRIEF-Zylox-Tonbridge Medical Technology Says Intention To Conduct On-Market Share Repurchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2530539391","media":"Reuters","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530539391?lang=en_us&edition=fundamental","pubTime":"2025-04-25 23:02","pubTimestamp":1745593348,"startTime":"0","endTime":"0","summary":"BRIEF-Zylox-Tonbridge Medical Technology Says Intention To Conduct On-Market Share RepurchaseApril 25  - Zylox-Tonbridge Medical Technology Co Ltd 2190.HK:INTENTION TO CONDUCT ON-MARKET SHARE REPURCHASE TO AMOUNT NOT EXCEEDING HKD650 MILLIONFurther company coverage: 2190.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nFWN3R30TW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02190","BK1574","BK1100","BK1587","BK1583"],"gpt_icon":0},{"id":"2530133070","title":"Zylox-Tonbridge Medical Technology -  Recommends Distribution of Final Dividend of RMB0.1 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2530133070","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530133070?lang=en_us&edition=fundamental","pubTime":"2025-04-25 21:04","pubTimestamp":1745586270,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nFWN3R30D7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02190","BK1587","BK1100","BK1583","BK1574"],"gpt_icon":0},{"id":"2530813854","title":"Zylox-Tonbridge Medical Technology - Intention to Conduct on-Market Share Repurchase to Amount Not Exceeding HKD650 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2530813854","media":"THOMSON REUTERS","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530813854?lang=en_us&edition=fundamental","pubTime":"2025-04-25 20:46","pubTimestamp":1745585190,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nFWN3R30TW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02190","BK1587","BK1583","BK1100","BK1574"],"gpt_icon":0},{"id":"2530818175","title":"InnoCare Pharma Gets China Nod for Lymphoma Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2530818175","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530818175?lang=en_us&edition=fundamental","pubTime":"2025-04-25 19:45","pubTimestamp":1745581513,"startTime":"0","endTime":"0","summary":"InnoCare Pharma  obtained approval for BTK inhibitor, Orelabrutinib, from China's National Medical Products Administration to treat chronic lymphocytic leukemia/small lymphocytic lymphoma, a Friday Hong Kong bourse filing said.Orelabrutinib has previously been approved for three indications in China, according to the pharmaceutical firm.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688428","BK1161","BK1574","09969","BK0239"],"gpt_icon":0},{"id":"2530390117","title":"BRIEF-Keymed Biosciences Announces Approval Of IND For Cm518d1 By The National Medical Products Administration Of China","url":"https://stock-news.laohu8.com/highlight/detail?id=2530390117","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530390117?lang=en_us&edition=fundamental","pubTime":"2025-04-25 17:48","pubTimestamp":1745574511,"startTime":"0","endTime":"0","summary":"BRIEF-Keymed Biosciences Announces Approval Of IND For Cm518d1 By The National Medical Products Administration Of China April 25 (Reuters) - Keymed Biosciences Inc 2162.HK:KEYMED BIOSCIENCES ANNOUNCES","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nTUA8MQPDT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1583","BK1161","02162","BK1574"],"gpt_icon":0},{"id":"2530097269","title":"KeyMed Biosciences Announces Approval of Ind for Cm518d1 by the National Medical Products Administration of China for the Treatment of Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2530097269","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530097269?lang=en_us&edition=fundamental","pubTime":"2025-04-25 17:44","pubTimestamp":1745574260,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nTUA6LMCSH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1587","BK1574","BK1583","02162","BK1161"],"gpt_icon":0},{"id":"2530065059","title":"KeyMed Biosciences Announces Approval of Ind for Cm518d1 by the National Medical Products Administration of China for the Treatment of Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2530065059","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530065059?lang=en_us&edition=fundamental","pubTime":"2025-04-25 17:24","pubTimestamp":1745573061,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nTUA8MQPDT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1587","BK1161","BK1574","BK1583","02162"],"gpt_icon":0},{"id":"2530905231","title":"Everest Medicines to Drop B Marker from Stock Short Name","url":"https://stock-news.laohu8.com/highlight/detail?id=2530905231","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530905231?lang=en_us&edition=fundamental","pubTime":"2025-04-25 17:20","pubTimestamp":1745572827,"startTime":"0","endTime":"0","summary":"Everest Medicines (HKG:1952) will cease to have the B marker attached to its stock short name from May 2, according to a Friday filing with the Hong Kong bourse.The biopharmaceutical company's new English stock short name will be EVEREST MED.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1574","BK1583","BK1161","MDCO","01952"],"gpt_icon":0},{"id":"2530288139","title":"US FDA Approves Nasopharyngeal Carcinoma Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2530288139","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530288139?lang=en_us&edition=fundamental","pubTime":"2025-04-25 12:41","pubTimestamp":1745556098,"startTime":"0","endTime":"0","summary":"The US Food and Drug Administration  approved Akeso's penpulimab-kcqx combination with cisplatin or carboplatin and gemcitabine for the treatment of nasopharyngeal carcinoma.The drug, a differentiated PD-1 monoclonal antibody, is indicated for the treatment of recurrent or metastatic non-keratinizing nasopharyngeal carcinoma in adults, according to a Friday filing with the Hong Kong bourse.Chinese authorities have already approved the drug for first-line treatment of advanced nasopharyngeal carcinoma and second or later-line treatment of advanced nasopharyngeal carcinoma, the filing said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0417516571.SGD","LU0348783233.USD","LU2488822045.USD","LU0348784397.USD","LU1720050803.USD","09926","LU1794554557.SGD","IE00B5MMRT66.SGD","IE00BPRC5H50.USD","BK1574","IE00B543WZ88.USD","BK1161"],"gpt_icon":0},{"id":"2530494268","title":"KeyMed Biosciences Announces Approval of Ind for Cm518d1 by the National Medical Products Administration of China for the Treatment of Gastrointestinal Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2530494268","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530494268?lang=en_us&edition=fundamental","pubTime":"2025-04-25 11:50","pubTimestamp":1745553039,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nTUA3BP08M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02162","BK1583","BK1161","BK1587","BK1574"],"gpt_icon":0},{"id":"2530094451","title":"KeyMed Biosciences Announces Approval of Ind for Cm518d1 by the National Medical Products Administration of China for the Treatment of Gastrointestinal Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2530094451","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530094451?lang=en_us&edition=fundamental","pubTime":"2025-04-25 11:37","pubTimestamp":1745552241,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nTUA8DXHL6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02162","BK1587","BK1161","BK1574","BK1583"],"gpt_icon":0},{"id":"2530911847","title":"BRIEF-Akeso Says FDA Approved Anniko (Penpulimab-Kcqx, Pd-1) In Two Indications","url":"https://stock-news.laohu8.com/highlight/detail?id=2530911847","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530911847?lang=en_us&edition=fundamental","pubTime":"2025-04-25 08:56","pubTimestamp":1745542619,"startTime":"0","endTime":"0","summary":"BRIEF-Akeso Says FDA Approved Anniko  In Two Indications April 25  - Akeso 9926.HK:FDA APPROVED ANNIKO  IN TWO INDICATIONS FOR COMPREHENSIVE TREATMENT OF ADVANCED NASOPHARYNGEAL CARCINOMAFurther company coverage: 9926.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nFWN3R23JY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0417516571.SGD","IE00B543WZ88.USD","LU0348783233.USD","LU2488822045.USD","09926","BK1161","BK1574","LU1720050803.USD","LU0348784397.USD","LU1794554557.SGD","IE00B5MMRT66.SGD","IE00BPRC5H50.USD"],"gpt_icon":0},{"id":"2530915758","title":"Akeso Announces FDA Approval for Penpulimab-Kcqx in Two Bla Indications for Comprehensive Treatment of Advanced Nasopharyngeal Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2530915758","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530915758?lang=en_us&edition=fundamental","pubTime":"2025-04-25 08:15","pubTimestamp":1745540122,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nTUA4BKKY1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1794554557.SGD","BK1574","LU0417516571.SGD","IE00BPRC5H50.USD","LU1720050803.USD","LU2488822045.USD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","09926","BK1161","LU0348784397.USD","LU0348783233.USD"],"gpt_icon":0},{"id":"2530139529","title":"Akeso - FDA Approved Anniko (Penpulimab-Kcqx, Pd-1) in Two Indications for Comprehensive Treatment of Advanced Nasopharyngeal Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2530139529","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530139529?lang=en_us&edition=fundamental","pubTime":"2025-04-25 07:50","pubTimestamp":1745538635,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250424:nFWN3R23JY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B5MMRT66.SGD","LU0417516571.SGD","BK1161","LU0348784397.USD","09926","BK1574","LU1720050803.USD","LU0348783233.USD","IE00BPRC5H50.USD","LU1794554557.SGD","LU2488822045.USD","IE00B543WZ88.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":41,"code":"91000000","status":"200"}]}}